These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
89 related articles for article (PubMed ID: 1037449)
1. FDA problems with medications in the marketplace: I. Archambault GF Hosp Formul; 1976 Apr; 11(4):224. PubMed ID: 1037449 [No Abstract] [Full Text] [Related]
2. Bioavailability and bioequivalence requirements: abbreviated applications. Final Rule. Food and Drug Administration, HHS Fed Regist; 2002 Dec; 67(244):77668-75. PubMed ID: 12492102 [TBL] [Abstract][Full Text] [Related]
3. Status of generic substitution: problematic drug classes reviewed. Ross MB Hosp Formul; 1989 Aug; 24(8):441-4, 447-9. PubMed ID: 10294356 [TBL] [Abstract][Full Text] [Related]
4. FDA problems with medications in the marketplace: III. 'Therapeutic orphans'. Archambault GF Hosp Formul; 1976 Dec; 11(12):690. PubMed ID: 1028797 [No Abstract] [Full Text] [Related]
5. FDA problems with medications in the marketplace: II. Archambault GF Hosp Formul; 1976 May; 11(5):272. PubMed ID: 1026690 [No Abstract] [Full Text] [Related]
6. What are narrow therapeutic index drugs? Levy G Clin Pharmacol Ther; 1998 May; 63(5):501-5. PubMed ID: 9630822 [No Abstract] [Full Text] [Related]
7. When do differences in dissolution profiles predict clinical problems? Ngo SN J Clin Pharm Ther; 2007 Apr; 32(2):111-2. PubMed ID: 17381660 [No Abstract] [Full Text] [Related]
8. FDA problems with medications in the marketplace: IV. Drugs and the unborn. Archambault GF Hosp Formul; 1977 Jan; 12(1):56. PubMed ID: 10236016 [No Abstract] [Full Text] [Related]
9. FDA issues requirement for retaining drug samples. Oncology (Williston Park); 1991 May; 5(5):176. PubMed ID: 1832001 [No Abstract] [Full Text] [Related]
10. Secretary upholds FDA on generics. Richards NM Pa Med; 1990 Jun; 93(6):28. PubMed ID: 2367133 [No Abstract] [Full Text] [Related]
11. Dilantin vs generic phenytoin sodium. Med Lett Drugs Ther; 1980 Jun; 22(12):49-50. PubMed ID: 7374622 [No Abstract] [Full Text] [Related]
12. Ten medical myths about FDA. Kennedy D West J Med; 1977 Dec; 127(6):529-34. PubMed ID: 595593 [No Abstract] [Full Text] [Related]
13. Perspectives. Hitting the FDA ... again. Wiener JO Faulkner Grays Med Health; 1990 Oct; 44(41):suppl 4 p.. PubMed ID: 10107287 [No Abstract] [Full Text] [Related]
14. Dosage form performance: a major factor in clinical medicine. Dittert LW Conn Med; 1976 May; 40(5):333-7. PubMed ID: 776529 [No Abstract] [Full Text] [Related]
15. Requirements for submission of bioequivalence data; final rule. Final rule. Food and Drug Administration, HHS Fed Regist; 2009 Jan; 74(11):2849-62. PubMed ID: 19385107 [TBL] [Abstract][Full Text] [Related]
16. Aspects for bioavailability and bioequivalence revision: possible implications on clinical pharmacology. Ritschel WA Methods Find Exp Clin Pharmacol; 1987 Jul; 9(7):453-9. PubMed ID: 3683020 [No Abstract] [Full Text] [Related]
17. Levothyroxine dosage and the limitations of current bioequivalence standards. Hennessey JV Nat Clin Pract Endocrinol Metab; 2006 Sep; 2(9):474-5. PubMed ID: 16957756 [No Abstract] [Full Text] [Related]
18. Generic drug scandals raise questions about safety. FDA reorganizes to increase surveillance, prevent fraud. Martin S Am Pharm; 1989 Oct; NS29(10):23-4. PubMed ID: 2816714 [No Abstract] [Full Text] [Related]
19. Challenges and opportunities in animal drug development: a regulatory perspective. Lathers CM Nat Rev Drug Discov; 2003 Nov; 2(11):915-8. PubMed ID: 14560318 [No Abstract] [Full Text] [Related]